Navigation Links
CareFusion Reports First Quarter Fiscal 2012 Results
Date:11/7/2011

SAN DIEGO, Nov. 7, 2011 /PRNewswire/ -- CareFusion today reported results for the quarter ended Sept. 30, 2011.

"Our revenue and adjusted earnings per share growth for the quarter was driven by increased sales in our Dispensing Technologies and Infusion Systems businesses and the benefit from a lower tax rate," said Kieran Gallahue, chairman and CEO. "During the quarter, we transitioned from our stand-up phase to our foundation building stage, and made progress in our efforts to simplify how we do business and invest in areas to help expand margins and accelerate our top line growth.

Today, we are reaffirming our full-year adjusted diluted earnings per share guidance for fiscal 2012 of $1.80 to $1.90 and revenue growth of 3 to 5 percent over fiscal 2011 on a constant currency basis."

CareFusion's reported results compare to the quarter ended Sept. 30, 2010.

First Quarter ResultsRevenue for the first quarter of fiscal 2012 increased 4 percent to $844 million on a reported basis and 3 percent on a constant currency basis, driven primarily by increased sales in the Dispensing Technologies and Infusion Systems businesses. Operating income was $108 million and income from continuing operations was $67 million, or $0.30 per diluted share. Excluding nonrecurring items, adjusted operating income increased $1 million to $119 million and adjusted income from continuing operations increased $12 million to $76 million, or $0.33 per diluted share. The adjusted tax rate for the quarter was 19.8 percent, primarily driven by a discrete onetime $5 million United Kingdom tax refund related to pre-spinoff periods from Cardinal Health.

CareFusion's financial results were negatively impacted during the quarter by an increase in recall reserves in the company's Medical Systems segment. The company recorded a $12 million charge, or approximately $0.04 per share, the majority of which is related to expenses incurred and future expected costs
'/>"/>

SOURCE CareFusion
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related biology technology :

1. ERT Closes the Acquisition of the Research Services Division of CareFusion Corporation
2. Sequenom, Inc. Reports Financial Results for the Third Quarter of 2011
3. InterMune Reports Third Quarter 2011 Financial Results and Business Highlights
4. Cumberland Pharmaceuticals Reports Third Quarter 2011 Financial Results
5. Optimer Pharmaceuticals Reports Third Quarter 2011 Financial Results
6. Caliper Life Sciences Reports Third Quarter 2011 Results
7. Neurocrine Biosciences Reports Third Quarter 2011 Results
8. United Therapeutics Corporation Reports Third Quarter 2011 Financial Results
9. Sangamo BioSciences Reports Third Quarter 2011 Financial Results
10. Cell Therapeutics, Inc. (CTI) Reports Third Quarter Financial Results and Milestones
11. ReportsnReports: Depression Therapeutics Market to Reach $10.9 Billion by 2018
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/22/2014)... solution of rod-shaped metal nanoparticles in water with ultrasound ... drill bits. Why? No one yet knows exactly. But ... (NIST) have clocked their speedand it,s fast. At up ... times faster than any nanoscale object submerged in liquid ... has opened up the possibility that they could be ...
(Date:7/22/2014)... DALLAS , July 22, 2014   ... replacement therapy using natural, bio-identical hormone pellets, today ... , MD to the company.   Dr. Rouzier is ... training physician.      Dr. Rouzier was ... at UCLA and is a board certified emergency ...
(Date:7/22/2014)... CTD Holdings, Inc. (OTCQB:CTDH), a manufacturer and ... and other markets, announced today that it has closed ... private investors led by Novit L.P., an investment arm ... involved the signing of a Securities Purchase Agreement under ... at a price per share of $1.00, resulting in ...
(Date:7/22/2014)... Rice Lake, Wisconsin (PRWEB) July 22, 2014 ... will be in attendance at the 2014 NCSL ... Florida. Booth #423 will feature CONDEC pressure ... balance style weights, and the new, customized sets, ... years ago to promote cooperative efforts in solving ...
Breaking Biology Technology:NIST shows ultrasonically propelled nanorods spin dizzyingly fast 2Dr. Neal Rouzier Joins BioTE Medical 2Dr. Neal Rouzier Joins BioTE Medical 3CTD Holdings Closes $1.725 Million Private Placement 2CTD Holdings Closes $1.725 Million Private Placement 3Rice Lake Weighing Systems Showcases Metrology Solutions for the 2014 NCSL International Workshop & Symposium 2
... Dr. Kyong S. Choe, of Kwangju, South Korea, has been ... outstanding contributions and achievements in the field of healthcare. ... Dr. Choe is currently practicing with Feldman, Fitzgerald ... periodontics and prosthodontics targeting implants and full prosthetic reconstruction.  He ...
... on Tel Aviv Stock Exchange. - Common Stock to List on both Tel ... the Ticker Symbol PLX -,- Company Anticipates Joining TASE,s TA-75, TA-100, Tel-Tech, Tel-Tech ... to Dual List on Tel Aviv Stock Exchange -- CARMIEL, Israel, Aug. 30 ... ...
... August 30, 2010 ... if ... var shortURL = ""; BitlyCB.alertResponse = ... to grab the first one. for (var r in data.results) { first_result = data.results[r]; break; } for ...
Cached Biology Technology:Dr. Kyong S. Choe Recognized by Strathmore's Who's Who Worldwide Publication 2Protalix BioTherapeutics to Dual List on Tel Aviv Stock Exchange 2Protalix BioTherapeutics to Dual List on Tel Aviv Stock Exchange 3Protalix BioTherapeutics to Dual List on Tel Aviv Stock Exchange 4Protalix BioTherapeutics to Dual List on Tel Aviv Stock Exchange 5Protalix BioTherapeutics to Dual List on Tel Aviv Stock Exchange 6Protalix BioTherapeutics to Dual List on Tel Aviv Stock Exchange 7Protalix BioTherapeutics to Dual List on Tel Aviv Stock Exchange 8Teriflunomide Significantly Reduced Annualized Relapse Rate and was Well Tolerated in MS Patients 2Teriflunomide Significantly Reduced Annualized Relapse Rate and was Well Tolerated in MS Patients 3Teriflunomide Significantly Reduced Annualized Relapse Rate and was Well Tolerated in MS Patients 4Teriflunomide Significantly Reduced Annualized Relapse Rate and was Well Tolerated in MS Patients 5Teriflunomide Significantly Reduced Annualized Relapse Rate and was Well Tolerated in MS Patients 6Teriflunomide Significantly Reduced Annualized Relapse Rate and was Well Tolerated in MS Patients 7Teriflunomide Significantly Reduced Annualized Relapse Rate and was Well Tolerated in MS Patients 8Teriflunomide Significantly Reduced Annualized Relapse Rate and was Well Tolerated in MS Patients 9
(Date:7/22/2014)... chances are you are), help may be on the ... developed a vaccine that can combat dust-mite allergies by ... the nano-sized vaccine package lowered lung inflammation by 83 ... the paper, published in the AAPS (American ... reason why it works, the researchers contend, is because ...
(Date:7/22/2014)... research team from the National Institute of Standards ... has demonstrated a dramatically improved technique for analyzing ... vibration "signatures." The new NIST technique is an ... spectroscopy, but one that delivers signals that are ... scattering, and 100 times stronger than obtained from ...
(Date:7/22/2014)... cost-effectiveness analysis of commercial diet programs and pills, the ... best value for the money. The Jenny Craig regimen ... most expensive option tested, according to researchers at Duke-National ... findings, published in the June issue of the journal ... and weight-loss benefits per dollar spent as insurance carriers ...
Breaking Biology News(10 mins):Researchers create vaccine for dust-mite allergies 2Enhanced NIST instrument enables high-speed chemical imaging of tissues 2Enhanced NIST instrument enables high-speed chemical imaging of tissues 3Study compares cost-effectiveness of weight-loss programs and drugs 2Study compares cost-effectiveness of weight-loss programs and drugs 3
... New discoveries by researchers at the University ... a first-ever pharmacological treatment for cocaine addiction. ... to treat people with hypertension and anxiety, has ... from retrieving memories associated with cocaine use in ...
... , STONY BROOK, NY"Trophic Downgrading of Planet Earth," a review ... the journal Science, concludes that the decline of ... is causing substantial changes to Earth,s terrestrial, freshwater, and marine ... from ecosystems "may be humankind,s most pervasive influence on nature." ...
... achieved a pivotal breakthrough in the development of a cable ... possible. Armchair quantum wire (AQW) will be a weave ... over long distances. It will be an ideal replacement for ... 5 percent per 100 miles of transmission, said Rice chemist ...
Cached Biology News:UWM research offers hope for treatment of cocaine addiction 2Loss of top animal predators has massive ecological effects 2Loss of top animal predators has massive ecological effects 3'Amplified' nanotubes may power the future 2'Amplified' nanotubes may power the future 3
HSV-2 gD (0191)...
...
...
RayBio Human Angiogenesis Antibody Array 2.1 (8 array membranes) with Accessory, detects 23 angiogenic factors (for lysate) Class: Antibody Array Products Product Group: Antibody Array...
Biology Products: